Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Tocilizumab

Catalog #:   DHC36902 Specific References (100) DATASHEET
Host species: Humanized
Isotype: IgG1
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC36902

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1

Clonality

Monoclonal

Target

sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08887

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Atlizumab, MRA, R-1569, RHPM-1, RO-4877533, CAS: 375823-41-9

Clone ID

Tocilizumab

Data Image
  • Bioactivity
    Detects Human CD126/IL6R/IL-6RA in indirect ELISAs.
  • SDS-PAGE
    SDS PAGE for Tocilizumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Tocilizumab: A Review in Rheumatoid Arthritis, PMID: 29094311

Tocilizumab for severe COVID-19: a systematic review and meta-analysis, PMID: 32712333

Tocilizumab: the first interleukin-6-receptor inhibitor, PMID: 18653811

Tocilizumab (Actemra), PMID: 28841363

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19, PMID: 32651997

[COVID-19: Still a place for tocilizumab?], PMID: 33288230

Tocilizumab in Covid-19, PMID: 33356049

Tocilizumab in transplantation, PMID: 32266480

Tocilizumab in Giant Cell Arteritis, PMID: 29570475

Efficacy of tocilizumab treatment in severely ill COVID-19 patients, PMID: 32854738

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial, PMID: 27156934

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia, PMID: 32575124

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes, PMID: 32553536

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial, PMID: 31469238

Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies, PMID: 33051695

Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies, PMID: 33296566

Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review, PMID: 32940187

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study, PMID: 27215218

Tocilizumab treatment for new onset refractory status epilepticus, PMID: 30408233

Tocilizumab, PMID: 20065633

Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?, PMID: 32353742

Effectiveness of tocilizumab in Behcet's disease: A systematic literature review, PMID: 32544751

Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease, PMID: 33045577

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade, PMID: 29207939

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial, PMID: 32333897

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate), PMID: 29066464

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome, PMID: 29622697

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia, PMID: 32405160

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study, PMID: 32979572

Tocilizumab: do not be the next chloroquine!, PMID: 32744721

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis, PMID: 30590833

Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19, PMID: 32822775

Tocilizumab in the treatment of giant cell arteritis, PMID: 29504436

Tocilizumab in Covid-19. Reply, PMID: 33356050

Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies, PMID: 33244947

Tocilizumab in the treatment of adult rheumatoid arthritis, PMID: 29495891

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study, PMID: 32569363

Tocilizumab for Giant Cell Arteritis, PMID: 32205653

Tocilizumab mimotope alleviates kidney injury and fibrosis by inhibiting IL-6 signaling and ferroptosis in UUO model, PMID: 32979361

Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review, PMID: 32107035

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, PMID: 18784373

Tocilizumab in the Management of COVID-19: A Preliminary Report, PMID: 33358502

Tocilizumab prescribing criteria for COVID-19 patients, PMID: 33079613

Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia, PMID: 33079980

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells, PMID: 32365119

Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction?, PMID: 32816393

Tocilizumab for treating juvenile idiopathic arthritis, PMID: 26848760

Tocilizumab in patients with severe COVID-19: A single-center observational analysis, PMID: 32628003

Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis, PMID: 33401328

Tocilizumab in Graves ophthalmopathy, PMID: 31493854

A Systematic Review of Anti-TNF and Anti-IL-6 Treatments for Pediatric Takayasu Arteritis: Addressing a Therapeutic Dilemma., PMID:40531440

PET-guided detection of relapse in large-vessel vasculitis during tocilizumab therapy: A comment on "Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice"., PMID:40527700

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial., PMID:40527572

Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study., PMID:40526615

Generation and Biological Characterization of an Anti-IL-6Rα Biosimilar Candidate Antibody., PMID:40524396

Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece., PMID:40520784

The sequential therapy for non-infectious scleritis: A case report., PMID:40520084

Interferon-β and interleukin-6 exert opposing effects on Foxp3 acetylation to control regulatory T cell induction., PMID:40519931

Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab., PMID:40516928

Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series., PMID:40510619

Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy., PMID:40510358

The clinical toxicity of advanced therapy medicinal products., PMID:40509780

Sarilumab in the treatment of rheumatoid arthritis: future perspectives., PMID:40506803

Pulmonary Aspergillosis: Epidemiology and unresolved diagnostic challenges - insights from a two-year retrospective cohort study in Marseille., PMID:40505837

Unravelling VEXAS syndrome: shedding light on a recently recognised medical condition., PMID:40499953

A rare case report: acute necrotizing encephalopathy and acute fulminant myocarditis., PMID:40495992

Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study., PMID:40495185

Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups., PMID:40489954

Management of Patients With COVID-19 During the Pandemic: A Retrospective Cohort Study From a Tertiary Care Centre in Mumbai, India., PMID:40486438

Minocycline in chronic management of febrile infection-related epilepsy syndrome (FIRES): a case series and literature review of treatment strategies., PMID:40481521

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650

Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755

Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three year follow-up., PMID:40478774

[VEXAS Syndrome]., PMID:40476413

Steroid refractory immune-related acute disseminated encephalomyelitis (ADEM) successfully treated with 2nd and 3rd line immunosuppressive therapy., PMID:40473324

[Clinical phenotype and genotype analysis of neuroinflammation, autoinflammation, splenomegaly and anemia syndrome caused by IRAK4 gene variant]., PMID:40468499

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report]., PMID:40462437

Baricitinib and Tocilizumab in COVID-19: A Call for Deeper Mechanistic and Methodological Exploration., PMID:40459395

IL-6R blockade combined with immunosuppressants alleviates adult-onset Still's disease through immune remodeling: a mass cytometry study., PMID:40457438

Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study., PMID:40454296

The first nationwide epidemiological survey of chronic recurrent multifocal osteomyelitis in Japan., PMID:40445191

Physician Burden and Time Delays in Initiating Immunomodulatory Therapy for Non-infectious Uveitis and Inflammatory Eye Diseases., PMID:40441503

Antibody-mediated Rejection - Treatment Standard., PMID:40440205

Mendelian randomisation and infection: pitfalls and promises., PMID:40435229

Successful treatment with tocilizumab in a case of familial Mediterranean fever with Takayasu arteritis., PMID:40433865

Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids., PMID:40432839

Efficacy of Tofacitinib in Takayasu Arteritis Refractory to Biologic DMARDs-A Multicentre Study in Indian Patients., PMID:40432338

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462

Experience of High Tibial Osteotomy for Patients with Rheumatoid Arthritis Treated with Recent Medication: A Case Series., PMID:40429328

Interactions of Probiotics with the Immune Cells of Patients with COVID-19 Pneumonia., PMID:40424990

Tocilizumab prophylaxis in double cord blood transplantation., PMID:40423984

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation., PMID:40423982

Polyangiitis overlap syndrome is a high-risk clinical phenotype for relapse: case series from the KEIO-vasculitis cohort., PMID:40421732

Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report., PMID:40419927

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders., PMID:40413020

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study., PMID:40412417

Integrative genome-wide association studies, proteome-wide Mendelian randomization, and single-cell RNA sequencing identify interleukin-6 receptor protein as a therapeutic target in aortic aneurysm., PMID:40409638

Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review., PMID:40406130

Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis., PMID:40404973

Datasheet

Document Download

Research Grade Tocilizumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Tocilizumab [DHC36902]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only